132 related articles for article (PubMed ID: 36605683)
1. A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome.
Oki R; Urasaki T; Ueki A; Inamura K; Komai Y; Takahashi S; Yonese J; Yuasa T
IJU Case Rep; 2023 Jan; 6(1):33-36. PubMed ID: 36605683
[TBL] [Abstract][Full Text] [Related]
2. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer 'mismatch' in Lynch syndrome.
Hendifar AE; Larson BK; Rojansky R; Guan M; Gong J; Placencio V; Tuli R; Hitchins M
BMJ Open Gastroenterol; 2019; 6(1):e000274. PubMed ID: 31275582
[TBL] [Abstract][Full Text] [Related]
5. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
6. Lynch Syndrome: A Primer for Urologists and Panel Recommendations.
Mork M; Hubosky SG; Rouprêt M; Margulis V; Raman J; Lotan Y; O'Brien T; You N; Shariat SF; Matin SF
J Urol; 2015 Jul; 194(1):21-9. PubMed ID: 25711197
[TBL] [Abstract][Full Text] [Related]
7. An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome.
Therkildsen C; Jensen LH; Rasmussen M; Bernstein I
Clin Exp Gastroenterol; 2021; 14():181-197. PubMed ID: 34079322
[TBL] [Abstract][Full Text] [Related]
8. Synchronous endometrial and ovarian cancer in Lynch syndrome with a
Takeda T; Banno K; Yanokura M; Anko M; Kobayashi A; Sera A; Takahashi T; Adachi M; Kobayashi Y; Hayashi S; Nomura H; Hirasawa A; Tominaga E; Aoki D
Mol Clin Oncol; 2018 Nov; 9(5):479-484. PubMed ID: 30402230
[TBL] [Abstract][Full Text] [Related]
9. Bilateral pleural effusion associated with atezolizumab in a patient with Lynch syndrome-related urothelial carcinoma: a case report.
Yhim HY; Jeon SY; Lee CH; Lee NR
Ann Palliat Med; 2022 Jun; 11(6):2162-2169. PubMed ID: 34328007
[TBL] [Abstract][Full Text] [Related]
10. Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report.
Feng Y; Cao Y; Yuan M; Chen R; Ji X; Hu X
Oncol Lett; 2019 Nov; 18(5):5085-5090. PubMed ID: 31612019
[TBL] [Abstract][Full Text] [Related]
11. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
[TBL] [Abstract][Full Text] [Related]
12. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma.
Metcalfe MJ; Petros FG; Rao P; Mork ME; Xiao L; Broaddus RR; Matin SF
J Urol; 2018 Jan; 199(1):60-65. PubMed ID: 28797715
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
[TBL] [Abstract][Full Text] [Related]
14. Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type.
Maccaroni E; Lenci E; Agostinelli V; Cognigni V; Giampieri R; Mazzanti P; Di Pietro Paolo M; Bianchi F; Brugiati C; Belvederesi L; Pagliaretta S; Mandolesi A; Scarpelli M; Murrone A; Morgese F; Ballatore Z; Berardi R
Explor Target Antitumor Ther; 2021; 2(3):240-248. PubMed ID: 36046437
[TBL] [Abstract][Full Text] [Related]
15. Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review.
Hodges A; Sun K; Sheu TG; Bernicker EH
Front Oncol; 2023; 13():1193503. PubMed ID: 37901336
[TBL] [Abstract][Full Text] [Related]
16. Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer.
Salman P; Panay S; Fernández R; Mahave M; Soza-Ried C
Onco Targets Ther; 2018; 11():7295-7300. PubMed ID: 30425520
[TBL] [Abstract][Full Text] [Related]
17. Thyroid cancer in a patient with Lynch syndrome - case report and literature review.
Fazekas-Lavu M; Parker A; Spigelman AD; Scott RJ; Epstein RJ; Jensen M; Samaras K
Ther Clin Risk Manag; 2017; 13():915-918. PubMed ID: 28769567
[TBL] [Abstract][Full Text] [Related]
18. Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report.
Batman S; Rauh-Hain JA; Grinsfelder MO; Harrison R; Avila M; Cun H; How JA; Tandon N; Wang X; Hinchcliff E; Jazaeri AA; Schmeler KM
Case Rep Oncol; 2023; 16(1):273-278. PubMed ID: 37123608
[TBL] [Abstract][Full Text] [Related]
19. Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab.
Kiyomiya M; Fukuda K; Shimazu K; Yoshida T; Taguchi D; Shinozaki H; Nanjyo H; Shibata H
Jpn J Clin Oncol; 2023 Mar; 53(3):270-274. PubMed ID: 36484308
[TBL] [Abstract][Full Text] [Related]
20. A pathological complete response after immunotherapy with pembrolizumab for distal duodenal adenocarcinoma caused by Lynch syndrome: a case report.
Ikeda S; Hu Q; Natsugoe K; Harima T; Tanaka Y; Kinoshita I; Nonaka K; Nambara S; Nakanishi R; Nakanoko T; Ota M; Kimura Y; Oki E; Oda Y; Yoshizumi T
Int Cancer Conf J; 2023 Oct; 12(4):279-284. PubMed ID: 37577343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
